Nova Patents
PL368901A1

Once-a-day oxycodone formulations

Abstract

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C 24 /C max oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.

Term

Term ended

Projected expiry passed 2 May 2022, 4.4 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

119 members in 32 offices

This recordMember, by publication datePriority claim22 more offices are in the list below

Priority claims4

Priority claims
DocumentOfficeKindDate
28821101United States of AmericaP
28821101United States of AmericaP
0160288211
US20010288211P

Members119

Family members, oldest first
DocumentOfficeKind
CA2474904A1CanadaA1
CA2601222A1CanadaA1
CA2601289A1CanadaA1
WO02087512A2World Intellectual Property Organization (WIPO)A2
IS7011AIcelandA
NO20034862D0NorwayD0
KR20030096342ARepublic of KoreaA
NO20034862LNorwayL
NO20130159LNorwayL
NO20160765LNorwayL
WO02087512A3World Intellectual Property Organization (WIPO)A3
MXPA03010079AMexicoA
EP1416921A2European Patent Office (EPO)A2
CZ20033242A3CzechiaA3
EA200301165A1Eurasian Patent Organization (EAPO)A1
CN1514721AChinaA
SK14622003A3SlovakiaA3
US2004170680A1United States of AmericaA1
JP2004528338AJapanA
HU0401601A2HungaryA2
MA27128A1MoroccoA1
ZA200308599BSouth AfricaB
AU2002303614B2AustraliaB2
HK1065482A1Hong Kong, ChinaA1
PL368901A1This recordPolandA1
PL388076A1PolandA1
EA005627B1Eurasian Patent Organization (EAPO)B1
HRP20030951A2CroatiaA2
TNSN03108A1TunisiaA1
KR20060028821ARepublic of KoreaA
YU86003AYugoslavia, later Serbia and Montenegro (until 2006)A
EP1416921A4European Patent Office (EPO)A4
KR100656730B1Republic of KoreaB1
KR20070030335ARepublic of KoreaA
UA81224C2UkraineC2
HU0401601A3HungaryA3
CA2474904CCanadaC
EP2011485A2European Patent Office (EPO)A2
KR20090037508ARepublic of KoreaA
JP2009108083AJapanA
NZ529231ANew ZealandA
UA88056C2UkraineC2
HK1128407A1Hong Kong, ChinaA1
KR20100003308ARepublic of KoreaA
CN101627974AChinaA
EP2011485A3European Patent Office (EPO)A3
UA92115C2UkraineC2
NZ576494ANew ZealandA
US7846476B2United States of AmericaB2
EP2269585A2European Patent Office (EPO)A2
EP2281555A2European Patent Office (EPO)A2
MEP49308AMontenegroA
JP4656815B2JapanB2
CA2601289CCanadaC
US2011104214A1United States of AmericaA1
KR20110047282ARepublic of KoreaA
ME00330BMontenegroB
KR101043492B1Republic of KoreaB1
HK1149722A1Hong Kong, ChinaA1
EP2269585A3European Patent Office (EPO)A3
KR20120028993ARepublic of KoreaA
NZ587010ANew ZealandA
EP2281555A3European Patent Office (EPO)A3
RS20110564A2SerbiaA2
CA2601222CCanadaC
KR20130018960ARepublic of KoreaA
RS20110564A3SerbiaA3
RS52577BSerbiaB
RS20120514A2SerbiaA2
KR20130100025ARepublic of KoreaA
JP2013189461AJapanA
IL158723AIsraelA
KR101366399B1Republic of KoreaB1
RS20120514A3SerbiaA3
CZ304442B6CzechiaB6
CN101627974BChinaB
SK288220B6SlovakiaB6
EP1416921B1European Patent Office (EPO)B1
PT1416921EPortugalE
DK1416921T3DenmarkT3
ES2523145T3SpainT3
EP2011485B1European Patent Office (EPO)B1
KR101476573B1Republic of KoreaB1
DK2011485T3DenmarkT3
HRP20030951B1CroatiaB1
HRP20140945A2CroatiaA2
SI1416921T1SloveniaT1
PT2011485EPortugalE
ES2530719T3SpainT3
SI2011485T1SloveniaT1
US2015140095A1United States of AmericaA1
CZ305211B6CzechiaB6
US2015231131A1United States of AmericaA1
JP5795138B2JapanB2
JP2015180669AJapanA
JP5805707B2JapanB2
NO337039B1NorwayB1
US2016030419A1United States of AmericaA1
EP2281555B1European Patent Office (EPO)B1
ES2571703T3SpainT3
Showing 100 of 119